NRXP Expands Access Protocol
NRx Pharmaceuticals announces FDA grant of expanded access protocol for use of D-Cycloserine-based NRX-101 for augmentation of transcranial magnetic stimulation in the treatment of depression
NRXP - NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression